Bosulf and T315I mutation – pro
Bosutinib (Bosulif®) is an orally administered small molecule tyrosine kinase inhibitor (TKI) of BCR-ABL and SRC family kinases. It is indicated for the treatment of adult patients with chronic-, accelerated-, or blast-phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy (imatinib, dasatinib, or nilotinib) [USA] In a multinational pivotal trial (n = 547), bosutinib treatment resulted in a major cytogenetic response (MCyR) at 24 weeks in one-third of all treated patients with imatinib-resistant chronic-phase CML who had no previous exposure to any TKIs other than imatinib (primary endpoint), with similar results observed in chronic-phase CML patients who were intolerant of imatinib and naïve to all other TKIs. MCyRs were also seen in more than one-quarter of evaluable patients with chronic-phase CML previously treated with multiple TKIs. Most of the patients with chronic-phase CML achieved a complete hematologic response with bosutinib and some patients with advanced phases of CML achieved an overall hematologic response. Responses were seen irrespective of the type of BCR-ABL mutation at baseline, except T315I.
The T315I mutation occurs in approximately 15% of imatinib-resistant patients with a ABL kinase domain mutation and may be more frequently detected in patients with advanced CML and Ph+ ALL As imatinib, nilotinib, dasatinib and bosutinib are not effective against the T315I mutation, treatment choices for patients with T315I mutations are very limited, with allogeneic transplantation or older drugs as options.
Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.BioDrugs. 2014 Feb;28(1):107-20.
Syed YY1, McCormack PL, Plosker GL.
Devendra K Hiwase; David T Yeung; Deborah L White, Optimizing the Selection of Kinase Inhibitors for Chronic Myeloid Leukemia Patients
Disclosures Expert Rev Hematol. 2011;4(3):285-299.